Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Calculated and TLD-based absorbed dose estimates for I-131-labeled 3F8 monoclonal antibody in a human neuroblastoma xenograft nude mouse model.

Ugur O, Scott AM, Kostakoglu L, Hui TE, Masterson ME, Febo R, Sgouros G, Rosa E, Mehta BM, Fisher DR, et al.

Nucl Med Biol. 1995 Jan;22(1):87-93.

PMID:
7735175
2.

Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses.

Ugur O, Kostakoglu L, Hui ET, Fisher DR, Garmestani K, Gansow OA, Cheung NK, Larson SM.

Nucl Med Biol. 1996 Jan;23(1):1-8.

PMID:
9004907
3.

Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice.

Cheung NK, Landmeier B, Neely J, Nelson AD, Abramowsky C, Ellery S, Adams RB, Miraldi F.

J Natl Cancer Inst. 1986 Sep;77(3):739-45.

PMID:
3091900
4.
5.
6.

Targeting of ganglioside GD2 monoclonal antibody to neuroblastoma.

Cheung NK, Neely JE, Landmeier B, Nelson D, Miraldi F.

J Nucl Med. 1987 Oct;28(10):1577-83.

7.

Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.

Buchsbaum DJ, Khazaeli MB, Mayo MS, Roberson PL.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3153s-3159s.

PMID:
10541357
8.

Targeting and therapy of human glioma xenografts in vivo utilizing radiolabeled antibodies.

Williams JA, Wessels BW, Edwards JA, Kopher KA, Wanek PM, Wharam MD, Order SE, Klein JL.

Cancer Res. 1990 Feb 1;50(3 Suppl):974s-979s.

9.

Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy.

Griffith MH, Yorke ED, Wessels BW, DeNardo GL, Neacy WP.

J Nucl Med. 1988 Nov;29(11):1795-809.

10.

Application of the cross-organ beta dose method for tissue dosimetry in tumor-bearing mice treated with a 90Y-labeled immunoconjugate.

Beatty BG, Kuhn JA, Hui TE, Fisher DR, Williams LE, Beatty JD.

Cancer. 1994 Feb 1;73(3 Suppl):958-65.

12.
13.
14.

Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma.

Heiner JP, Miraldi F, Kallick S, Makley J, Neely J, Smith-Mensah WH, Cheung NK.

Cancer Res. 1987 Oct 15;47(20):5377-81.

15.

Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.

Behr TM, Wulst E, Radetzky S, Blumenthal RD, Dunn RM, Gratz S, Rave-Fränk M, Schmidberger H, Raue F, Becker W.

Cancer Res. 1997 Dec 1;57(23):5309-19.

16.

Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry.

Behr TM, Sharkey RM, Sgouros G, Blumenthal RD, Dunn RM, Kolbert K, Griffiths GL, Siegel JA, Becker WS, Goldenberg DM.

Cancer. 1997 Dec 15;80(12 Suppl):2591-610.

PMID:
9406714
17.
18.

Targeting of human glioma xenografts in vivo utilizing radiolabeled antibodies.

Williams JA, Wessels BW, Wharam MD, Order SE, Wanek PM, Poggenburg JK, Klein JL.

Int J Radiat Oncol Biol Phys. 1990 Jun;18(6):1367-75.

PMID:
2370186
19.

High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.

Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.

Cancer Res. 1999 Jun 1;59(11):2635-43.

20.

Monoclonal antibody-targeted radiotherapy of renal cell carcinoma using a nude mouse model.

Chiou RK, Vessella RL, Limas C, Shafer RB, Elson MK, Arfman EW, Lange PH.

Cancer. 1988 May 1;61(9):1766-75.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk